Kentucky Retirement Systems Has $6.34 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Kentucky Retirement Systems reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 152,755 shares of the biopharmaceutical company’s stock after selling 1,771 shares during the quarter. Kentucky Retirement Systems’ holdings in Bristol-Myers Squibb were worth $6,344,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Gryphon Financial Partners LLC boosted its position in shares of Bristol-Myers Squibb by 23.5% during the 4th quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock worth $280,000 after acquiring an additional 995 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Bristol-Myers Squibb by 12.0% in the 4th quarter. Clearbridge Investments LLC now owns 125,980 shares of the biopharmaceutical company’s stock valued at $6,464,000 after purchasing an additional 13,534 shares in the last quarter. Sachetta LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $57,000. CreativeOne Wealth LLC raised its holdings in shares of Bristol-Myers Squibb by 34.7% during the 4th quarter. CreativeOne Wealth LLC now owns 17,827 shares of the biopharmaceutical company’s stock worth $915,000 after buying an additional 4,592 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of Bristol-Myers Squibb by 10.9% during the 4th quarter. Assetmark Inc. now owns 155,684 shares of the biopharmaceutical company’s stock worth $7,988,000 after buying an additional 15,329 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a report on Monday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. Jefferies Financial Group boosted their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. Finally, Barclays increased their price target on Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a research note on Thursday, August 22nd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $55.00.

Bristol-Myers Squibb Trading Up 0.5 %

NYSE BMY opened at $49.74 on Thursday. The firm has a market capitalization of $100.83 billion, a PE ratio of -16.05, a price-to-earnings-growth ratio of 12.59 and a beta of 0.46. The business’s 50-day moving average price is $47.34 and its two-hundred day moving average price is $46.48. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $59.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. The business had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.75 earnings per share. On average, analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.83%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.